GSK PLC (ADR) (GSK) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 84% based on the firm’s underlying fundamentals and the stock’s valuation.

The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value ... For investors seeking a more comprehensive analysis, InvestingPro offers ...

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, ...

The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value ... For investors seeking a more comprehensive analysis, InvestingPro offers 11 ...

For further insights into GSK stock, check out TipRanks’ Stock Analysis page. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

US drugmaker Eli Lilly looked set to lose a whopping $730 million in the stock market value on Wednesday, if its lunchtime ...

The price-to-earnings ratio for GSK Plc ADR (NYSE: GSK) is above average at 15.31x, Company’s 36-month beta value is 0.66.Analysts have differing opinions on the stock, with 0 analysts rating it as a ...

Further analysis of these data is ongoing ... acting biologic administered once every six months. Price Action: GSK stock is up 0.80% at $39.14 during the premarket session at last check Monday.